drugset / Trial / NCT01670799

Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01670799

Phase 0 Completed 29 enrolled New Mexico Cancer Research Alliance
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the anti-cancer effect of a pain medication called ketorolac (Toradol) on ovarian cancer cells in the abdominal (peritoneal) cavity after surgery for ovarian, fallopian tube or primary peritoneal cancer.

Timeline

Start
2012-03
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Other / unclassified 15 mg Intravenous
Subject Ketorolac Other / unclassified 30 mg Intravenous